These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 19336015)

  • 1. Novel hormonal approaches in prostate cancer.
    Friedlander TW; Ryan CJ
    Curr Oncol Rep; 2009 May; 11(3):227-34. PubMed ID: 19336015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the androgen receptor signaling pathway in advanced prostate cancer.
    Chung C; Abboud K
    Am J Health Syst Pharm; 2022 Jul; 79(15):1224-1235. PubMed ID: 35390118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel hormonal therapy for castration-resistant prostate cancer.
    Sternberg CN
    Ann Oncol; 2012 Sep; 23 Suppl 10():x259-63. PubMed ID: 22987973
    [No Abstract]   [Full Text] [Related]  

  • 4. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Castration-resistant prostate cancer: locking up the molecular escape routes.
    Attar RM; Takimoto CH; Gottardis MM
    Clin Cancer Res; 2009 May; 15(10):3251-5. PubMed ID: 19447877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
    Sharifi N
    Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiandrogens in prostate cancer endocrine therapy.
    Culig Z; Bartsch G; Hobisch A
    Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A road map to comprehensive androgen receptor axis targeting for castration-resistant prostate cancer.
    Mitsiades N
    Cancer Res; 2013 Aug; 73(15):4599-605. PubMed ID: 23887973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hormonal Therapy for Prostate Cancer.
    Desai K; McManus JM; Sharifi N
    Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Investigational therapies targeting the androgen signaling axis and the androgen receptor and in prostate cancer - recent developments and future directions.
    Isaacsson Velho P; Carducci MA
    Expert Opin Investig Drugs; 2018 Oct; 27(10):811-822. PubMed ID: 30118330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular biology of castration-resistant prostate cancer: basis for the novel therapeutic targets.
    Mellado B; Marin Aguilera M; Pereira MV
    Arch Esp Urol; 2013 Jun; 66(5):453-62. PubMed ID: 23793763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from in-vivo models of castration-resistant prostate cancer.
    Lin D; Gout PW; Wang Y
    Curr Opin Urol; 2013 May; 23(3):214-9. PubMed ID: 23385975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
    Bedoya DJ; Mitsiades N
    Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
    [No Abstract]   [Full Text] [Related]  

  • 15. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
    Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
    Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The truth is out there: an overall perspective on androgen deprivation.
    Hellerstedt BA; Pienta KJ
    Urol Oncol; 2003; 21(4):272-81. PubMed ID: 12954498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen annihilation as a new therapeutic paradigm in advanced prostate cancer.
    Rove KO; Crawford ED
    Curr Opin Urol; 2013 May; 23(3):208-13. PubMed ID: 23492838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR; Hussain MH
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A molecule inducing androgen receptor degradation and selectively targeting prostate cancer cells.
    Auvin S; Öztürk H; Abaci YT; Mautino G; Meyer-Losic F; Jollivet F; Bashir T; de Thé H; Sahin U
    Life Sci Alliance; 2019 Aug; 2(4):. PubMed ID: 31431473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel Insights into Molecular Indicators of Response and Resistance to Modern Androgen-Axis Therapies in Prostate Cancer.
    Silberstein JL; Taylor MN; Antonarakis ES
    Curr Urol Rep; 2016 Apr; 17(4):29. PubMed ID: 26902623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.